<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40054026</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-2782</ISSN><JournalIssue CitedMedium="Internet"><Volume>187</Volume><PubDate><Year>2025</Year><Month>Feb</Month><Day>26</Day></PubDate></JournalIssue><Title>Neural networks : the official journal of the International Neural Network Society</Title><ISOAbbreviation>Neural Netw</ISOAbbreviation></Journal><ArticleTitle>Dataset-free weight-initialization on restricted Boltzmann machine.</ArticleTitle><Pagination><StartPage>107297</StartPage><MedlinePgn>107297</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neunet.2025.107297</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0893-6080(25)00176-5</ELocationID><Abstract><AbstractText>In feed-forward neural networks, dataset-free weight-initialization methods such as LeCun, Xavier (or Glorot), and He initializations have been developed. These methods randomly determine the initial values of weight parameters based on specific distributions (e.g., Gaussian or uniform distributions) without using training datasets. To the best of the authors' knowledge, such a dataset-free weight-initialization method is yet to be developed for restricted Boltzmann machines (RBMs), which are probabilistic neural networks consisting of two layers. In this study, we derive a dataset-free weight-initialization method for Bernoulli-Bernoulli RBMs based on statistical mechanical analysis. In the proposed weight-initialization method, the weight parameters are drawn from a Gaussian distribution with zero mean. The standard deviation of the Gaussian distribution is optimized based on our hypothesis that a standard deviation providing a larger layer correlation (LC) between the two layers improves the learning efficiency. The expression of the LC is derived based on a statistical mechanical analysis. The optimal value of the standard deviation corresponds to the maximum point of the LC. The proposed weight-initialization method is identical to Xavier initialization in a specific case (i.e., when the sizes of the two layers are the same, the random variables of the layers are {-1,1}-binary, and all bias parameters are zero). The validity of the proposed weight-initialization method is demonstrated in numerical experiments using a toy dataset and real-world datasets.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yasuda</LastName><ForeName>Muneki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Graduate School of Science and Engineering, Yamagata University, Jonan 4-3-16, Yonezawa, 992-8510, Yamagata, Japan. Electronic address: muneki@yz.yamagata-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeno</LastName><ForeName>Ryosuke</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Techno Provide Inc., Honcho 1-1-8, Aoba-ku, Sendai, 980-0014, Miyagi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Chako</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Graduate School of Science and Engineering, Yamagata University, Jonan 4-3-16, Yonezawa, 992-8510, Yamagata, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neural Netw</MedlineTA><NlmUniqueID>8805018</NlmUniqueID><ISSNLinking>0893-6080</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Learning parameter initialization</Keyword><Keyword MajorTopicYN="N">Mean-field analysis</Keyword><Keyword MajorTopicYN="N">Replica method</Keyword><Keyword MajorTopicYN="N">Restricted Boltzmann machine</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Muneki Yasuda reports financial support was provided by JSPS KAKENHI. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40054026</ArticleId><ArticleId IdType="doi">10.1016/j.neunet.2025.107297</ArticleId><ArticleId IdType="pii">S0893-6080(25)00176-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40054011</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2057-1976</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>Biomedical physics &amp; engineering express</Title><ISOAbbreviation>Biomed Phys Eng Express</ISOAbbreviation></Journal><ArticleTitle>Prediction of preoperative tumor-related epilepsy using XGBoost radiomics models with 4 MRI sequences.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1088/2057-1976/adbdd3</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Tumor-related epilepsy is a prevalent condition in patients with gliomas. Accurate prediction of epilepsy is crucial for early treatment. This study aimed to evaluate the novel application of the eXtreme Gradient Boost (XGBoost) machine learning (ML) algorithm into a radiomics model predicting preoperative tumor-related epilepsy (PTRE). Its performance was compared with 4 conventional ML algorithms, including the least absolute shrinkage and selection operator (LASSO), elastic net, random forest, and support vector machine.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study used four magnetic resonance imaging (MRI) images consisting of four sequences (T1-weighted [T1W], T1-weighted contrast [T1WC], T2-weighted [T2W], and T2-weighted fluid-attenuated inversion recovery [T2W FLAIR]) acquired from 74 glioma patients, 30 with PTRE and 44 without PTRE. 394 radiomics features were extracted from the MRI scans using Pyradiomics, alongside 12 clinical features from the medical records. The ML algorithms were mixed and matched to create 20 radiomics models with two stages for: (1) feature selection and (2) prediction of PTRE. Nested cross-validation was used to tune the algorithms and select the stable features.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The XGBoost radiomics model demonstrated the second-highest balanced accuracy and F1-score of 0.81 &#xb1; 0.01 and 0.80 &#xb1; 0.01 respectively. It also achieved the highest recall of 0.81 &#xb1; 0.02. It used mostly textural radiomics features from the T1W, T2W and T2W FLAIR sequences to make the predictions.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study demonstrates that XGBoost is a viable alternative to conventional ML algorithms for developing a radiomics model to predict PTRE, as the model produced from XGBoost had among the highest metrics. XGBoost selected features with a higher predictive value than other models. The features selected by XGBoost were more stable, which is a useful property for radiomics analysis. Features selected from multiple MRI sequences were important in the model's decision.</AbstractText><CopyrightInformation>&#xa9; 2025 IOP Publishing Ltd. All rights, including for text and data mining, AI training, and similar technologies, are reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>George</LastName><ForeName>Reuben</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0890-5317</Identifier><AffiliationInfo><Affiliation>Faculty of Engineering, Technology and Built environment, UCSI University, No.1, Jalan UCSI, UCSI Heights,, Jalan Puncak Menara Gading, CHERAS, CHERAS, Kuala Lumpur, 56000, MALAYSIA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Li Sze</ForeName><Initials>LS</Initials><Identifier Source="ORCID">0000-0003-3877-4434</Identifier><AffiliationInfo><Affiliation>Department of Electrical and Electronic Engineering, UCSI University, No.1, Jalan UCSI, UCSI Heights,, Jalan Puncak Menara Gading, Taman Connaught,, CHERAS, Kuala Lumpur, 56000, MALAYSIA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Kheng Seang</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Medicine, Universiti Malaya, Jln Profesor Diraja Ungku Aziz, Seksyen 13, 50603 Petaling Jaya, Petaling Jaya, Kuala Lumpur, 50603, MALAYSIA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramli</LastName><ForeName>Norlisah</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biomedical Imaging, Universiti Malaya Faculty of Medicine, Jln Profesor Diraja Ungku Aziz, Seksyen 13, 50603 Petaling Jaya, Kuala Lumpur, Wilayah Persekutuan, 50603, MALAYSIA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Li Kuo</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Department of Biomedical Imaging, Faculty of Medicine, Universiti Malaya, Jln Profesor Diraja Ungku Aziz,, Seksyen 13, 50603 Petaling Jaya, Kuala Lumpur, Wilayah Persekutuan, 50603, MALAYSIA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solihin</LastName><ForeName>Mahmud Iwan</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Mechanical and Mechatronics Engineering, UCSI, No.1, Jalan UCSI, UCSI Heights,, Jalan Puncak Menara Gading, CHERAS, Cheras, Kuala Lumpur, 56000, MALAYSIA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biomed Phys Eng Express</MedlineTA><NlmUniqueID>101675002</NlmUniqueID><ISSNLinking>2057-1976</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Magnetic resonance imaging</Keyword><Keyword MajorTopicYN="N">XGBoost</Keyword><Keyword MajorTopicYN="N">radiomics</Keyword><Keyword MajorTopicYN="N">tumor-related epilepsy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>17</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40054011</ArticleId><ArticleId IdType="doi">10.1088/2057-1976/adbdd3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40053984</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1079-7114</ISSN><JournalIssue CitedMedium="Internet"><Volume>134</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>21</Day></PubDate></JournalIssue><Title>Physical review letters</Title><ISOAbbreviation>Phys Rev Lett</ISOAbbreviation></Journal><ArticleTitle>Switching Two-Dimensional Sliding Ferroelectrics by Mechanical Bending.</ArticleTitle><Pagination><StartPage>076101</StartPage><MedlinePgn>076101</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1103/PhysRevLett.134.076101</ELocationID><Abstract><AbstractText>Two-dimensional van der Waals materials, possessing a unique stacking degree of freedom, offer an alternative strategy for modulating their properties through interlayer sliding. Controlling the stacking order is crucial for tuning material properties and developing slidetronics-based devices. Here, using machine-learning potentials, we propose a mechanical bending approach to manipulate stacking orders and related properties in sliding ferroelectric h-BN, 3R-MoS_{2}, and nonferroelectric bilayer graphene. Our simulations predict the formation of irreversible kinks in bent bilayers, deviating from the expected arclike deformation. This kink formation arises from the interplay between bending energy and interlayer stacking energy. Notably, the bending-induced kink contains a ferroelectric topological domain wall that reverses the polarization of sliding ferroelectrics, a mechanism distinct from the conventional flexoelectric effect. This work proposes an exciting mechanical bending approach to dynamically manipulate the stacking order and associated optical, topological, ferroelectric, and magnetic properties in van der Waals layered materials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Ri</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ningbo Institute of Materials Technology and Engineering, Key Laboratory of Magnetic Materials Devices and Zhejiang Province Key Laboratory of Magnetic Materials and Application Technology, Chinese Academy of Sciences, Ningbo 315201, China.</Affiliation><Identifier Source="ROR">https://ror.org/05nqg3g04</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, College of Materials Science and Opto-Electronic Technology, Beijing 100049, China.</Affiliation><Identifier Source="ROR">https://ror.org/05qbk4x57</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Zhejiang University, Center for Quantum Matter, School of Physics, Hangzhou 310058, China.</Affiliation><Identifier Source="ROR">https://ror.org/00a2xv884</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Fenglin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University of Science and Technology of China, Suzhou Institute for Advanced Research, Suzhou 215123, China.</Affiliation><Identifier Source="ROR">https://ror.org/04c4dkn09</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Yuxiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>University of Science and Technology of China, Suzhou Institute for Advanced Research, Suzhou 215123, China.</Affiliation><Identifier Source="ROR">https://ror.org/04c4dkn09</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bingwen</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Minjiang University, Fujian Key Laboratory of Functional Marine Sensing Materials, Center for Advanced Marine Materials and Smart Sensors, College of Material and Chemical Engineering, Fuzhou 350108, China.</Affiliation><Identifier Source="ROR">https://ror.org/00s7tkw17</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yubai</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ningbo Institute of Materials Technology and Engineering, Key Laboratory of Magnetic Materials Devices and Zhejiang Province Key Laboratory of Magnetic Materials and Application Technology, Chinese Academy of Sciences, Ningbo 315201, China.</Affiliation><Identifier Source="ROR">https://ror.org/05nqg3g04</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, College of Materials Science and Opto-Electronic Technology, Beijing 100049, China.</Affiliation><Identifier Source="ROR">https://ror.org/05qbk4x57</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Run-Wei</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Ningbo Institute of Materials Technology and Engineering, Key Laboratory of Magnetic Materials Devices and Zhejiang Province Key Laboratory of Magnetic Materials and Application Technology, Chinese Academy of Sciences, Ningbo 315201, China.</Affiliation><Identifier Source="ROR">https://ror.org/05nqg3g04</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, College of Materials Science and Opto-Electronic Technology, Beijing 100049, China.</Affiliation><Identifier Source="ROR">https://ror.org/05qbk4x57</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, School of Future Technology, Beijing 100049, China.</Affiliation><Identifier Source="ROR">https://ror.org/05qbk4x57</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Zhicheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>University of Science and Technology of China, Suzhou Institute for Advanced Research, Suzhou 215123, China.</Affiliation><Identifier Source="ROR">https://ror.org/04c4dkn09</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>University of Science and Technology of China, School of Artificial Intelligence and Data Science, Suzhou 215123, China.</Affiliation><Identifier Source="ROR">https://ror.org/04c4dkn09</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Phys Rev Lett</MedlineTA><NlmUniqueID>0401141</NlmUniqueID><ISSNLinking>0031-9007</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>17</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40053984</ArticleId><ArticleId IdType="doi">10.1103/PhysRevLett.134.076101</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40053865</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-5207</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>The journal of physical chemistry. B</Title><ISOAbbreviation>J Phys Chem B</ISOAbbreviation></Journal><ArticleTitle>Identification of Novel Fourth-Generation Allosteric Inhibitors Targeting Inactive State of EGFR T790M/L858R/C797S and T790M/L858R Mutations: A Combined Machine Learning and Molecular Dynamics Approach.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jpcb.4c07651</ELocationID><Abstract><AbstractText>Targeted therapy with an allosteric inhibitor (AIs) is an important area of research in patients with epidermal growth factor receptor (EGFR) mutations. Current treatment of nonsmall cell lung cancer patients with EGFR mutations using orthosteric inhibitors faces challenges like resistance and stopping over phosphorylation. Notably AIs have been introduced to overcome this resistance and increase inhibitory potency that binds to pockets other than the ATP-binding site (orthosteric site). Recently, fourth-generation AIs, EAI045, have been discovered to potently and selectively inhibit various EGFR mutations but limited antiproliferative effects in the absence of the antibody cetuximab. The purpose of this work is to identify nontoxic, potent small AIs through various screening pipelines and explore their molecular mechanism. In the discovery of AIs, structural similarity search, high-throughput virtual screening, and machine learning-guided QSAR modeling, several candidates were identified. Machine learning was employed to guide the QSAR model based on 2D descriptors and DFT-derived quantum chemical descriptors followed by a PCA reduction technique, which enabled the prediction of the biological activity (IC<sub>50</sub>) of screened drugs against various EGFR mutations such as T790M/L858R/C797S and T790M/L858R. In addition, multinanosecond (ns) and microsecond (&#x3bc;s) classical molecular dynamics (MD) simulations run on protein-ligand binding complex to check the stability of binding dynamics for T790M/L858R/C797S and T790M/L858R mutations with lower IC<sub>50</sub> and higher docking score compounds. The molecular mechanics generalized Boltzmann surface area (MM/GBSA) calculation revealed that the five hit allosteric molecules for T790M/C797S/L858R and two for T790M/L858R mutations had a high binding affinity. The results were corroborated further by MM/GBSA employing the normal-mode analysis entropy method to perform additional screening. Furthermore, the compounds' efficacy was confirmed using path-dependent ligand unbinding free energy techniques such as Jarzynski averaged free energy profiles obtained from adaptive steered MD, relative residence time, and umbrella sampling simulations, which were compared to a reference inhibitor. However, path-independent alchemical approaches like streamlined alchemical free energy perturbation and binding free energy estimator 2 (BFEE2) were employed to validate the results and identify potent compounds. These findings pave the way to identification of novel potential fourth-generation AIs, which require further experimental validation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhanja</LastName><ForeName>Kousik K</ForeName><Initials>KK</Initials><Identifier Source="ORCID">0009-0009-0765-3315</Identifier><AffiliationInfo><Affiliation>Department of Chemistry &amp; Chemical Biology, Indian Institute of Technology (ISM), Dhanbad, Dhanbad 826004, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patra</LastName><ForeName>Niladri</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0331-2670</Identifier><AffiliationInfo><Affiliation>Department of Chemistry &amp; Chemical Biology, Indian Institute of Technology (ISM), Dhanbad, Dhanbad 826004, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Phys Chem B</MedlineTA><NlmUniqueID>101157530</NlmUniqueID><ISSNLinking>1520-5207</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>15</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40053865</ArticleId><ArticleId IdType="doi">10.1021/acs.jpcb.4c07651</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40053853</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2969-8960</ISSN><JournalIssue CitedMedium="Internet"><Volume>57</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The journal of extra-corporeal technology</Title><ISOAbbreviation>J Extra Corpor Technol</ISOAbbreviation></Journal><ArticleTitle>Limiting the gamble: Risk and predictability for renal replacement therapy in patients receiving mechanical circulatory support&#x2605;.</ArticleTitle><Pagination><StartPage>14</StartPage><EndPage>17</EndPage><MedlinePgn>14-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1051/ject/2024041</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients receiving mechanical circulatory support (MCS) frequently require renal replacement therapy (RRT). Examining risk factors for requiring RRT in patients receiving MCS may allow improved understanding of these comorbidities and enhance patient outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Following IRB approval, patient characteristics, comorbidities, and the need for RRT were studied in 129 patients who received MCS from January 2017 to October 2023. The clinical variables underwent machine learning to examine their relationships to the outcome of interest, the need for RRT.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In this study, the incidence of RRT was 36% with a 95% confidence interval ranging from 29% to 44%. Following machine learning, patients with a history of immunologic therapy or having a pacemaker or internal cardiac defibrillator (ICD) were associated with the need for RRT (&#x3c7;<sup>2</sup>&#xa0;=&#xa0;44, P&#xa0;=&#xa0;0.0003). The c-index statistic for this model was 0.81. The anticoagulation therapy administered in these two groups was also analyzed. Patients in these two groups receiving unfractionated heparin were observed to have a higher incidence (44%) in the need for RRT.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The incidence of RRT was high in this patient population. The novel associations in patients requiring MCS who have received prior immunologic therapy or have pre-existing pacemaker/ICDs suggest that an increased systemic inflammatory state exists that escalates the need for RRT. Unfractionated heparin appears to provide minimal protection from the need for RRT in patients requiring MCS. These findings suggest that other options for systemic anticoagulation in patients requiring MCS should be considered. Further investigation into how these background inflammatory conditions contribute to the need for RRT in patients requiring MCS is warranted.</AbstractText><CopyrightInformation>&#xa9; The Author(s), published by EDP Sciences, 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gore</LastName><ForeName>Kelsey</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0002-4248-3752</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Perfusion and Extracorporeal Technology, Ochsner Health, 1514 Jefferson Highway, New Orleans, Louisiana 70121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linder</LastName><ForeName>Dean</ForeName><Initials>D</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Cardiovascular Perfusion and Extracorporeal Technology, Ochsner Health, 1514 Jefferson Highway, New Orleans, Louisiana 70121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez Duque</LastName><ForeName>Juan Jos&#xe9;</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>CES University, Cl 10A #22-04, El Poblado, Medellin, Antioquia, Columbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Junxi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The University of Queensland Medical School, 288 Herston Road, Herston, QLD 4006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wester</LastName><ForeName>Brett</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Critical Care Section, Anesthesiology &amp; Perioperative Medicine, Ochsner Health, 1514 Jefferson Highway, New Orleans, Louisiana 70121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otero</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Critical Care Section, Anesthesiology &amp; Perioperative Medicine, Ochsner Health, 1514 Jefferson Highway, New Orleans, Louisiana 70121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yockelson</LastName><ForeName>Shaun</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4828-6437</Identifier><AffiliationInfo><Affiliation>Critical Care Section, Anesthesiology &amp; Perioperative Medicine, Ochsner Health, 1514 Jefferson Highway, New Orleans, Louisiana 70121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Adrian Alexis</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Critical Care Section, Anesthesiology &amp; Perioperative Medicine, Ochsner Health, 1514 Jefferson Highway, New Orleans, Louisiana 70121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nossaman</LastName><ForeName>Bobby D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Critical Care Section, Anesthesiology &amp; Perioperative Medicine, Ochsner Health, 1514 Jefferson Highway, New Orleans, Louisiana 70121, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>J Extra Corpor Technol</MedlineTA><NlmUniqueID>0267637</NlmUniqueID><ISSNLinking>0022-1058</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017582" MajorTopicYN="Y">Renal Replacement Therapy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="N">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anticoagulation</Keyword><Keyword MajorTopicYN="N">Extracorporeal membrane oxygenation (ECMO)</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Mechanical circulatory support (MCS)</Keyword><Keyword MajorTopicYN="N">Renal replacement therapy (RRT)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>15</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40053853</ArticleId><ArticleId IdType="doi">10.1051/ject/2024041</ArticleId><ArticleId IdType="pii">ject240022</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jung C, Bruno RR, Jumean M, et al. Management of cardiogenic shock: state-of-the-art. Intensive Care Med. 2024;50:1814&#x2013;1829. https://doi.org/10.1007/s00134-024-07618-x.</Citation></Reference><Reference><Citation>Barssoum K, Patel HP, Abdelmaseih R, et al. Characteristics and outcomes of early vs late initiation of mechanical circulatory support in non-acute myocardial infarction related cardiogenic shock: an analysis of the national inpatient sample database. Curr Probl Cardiol. 2023;48(5):101584. https://doi.org/10.1016/j.cpcardiol.2023.101584.</Citation></Reference><Reference><Citation>Versteilen AM, Di Maggio F, Leemreis JR, Groeneveld AB, Musters RJ, Sipkema P. Molecular mechanisms of acute renal failure following ischemia/reperfusion. Int J Artif Organs. 2004;27(12):1019&#x2013;1029. https://doi.org/10.1177/039139880402701203.</Citation></Reference><Reference><Citation>Abadeer AI, Kurlansky P, Chiuzan C, et al. Importance of stratifying acute kidney injury in cardiogenic shock resuscitated with mechanical circulatory support therapy. J Thorac Cardiovasc Surg. 2017;154(3):856&#x2013;864.e4. https://doi.org/10.1016/j.jtcvs.2017.04.042.</Citation></Reference><Reference><Citation>Tam CW, Shen L, Zeidman AD, Srivastava A, Ivascu NS. Mechanical circulatory support: primer for consultant specialists. Clin J Am Soc Nephrol. 2022;17(6):890&#x2013;901. https://doi.org/10.2215/CJN.13341021.</Citation></Reference><Reference><Citation>Kilburn DJ, Shekar K, Fraser JF. The complex relationship of extracorporeal membrane oxygenation and acute kidney injury: causation or association? Biomed Res Int. 2016;2016:1094296. https://doi.org/10.1155/2016/1094296.</Citation></Reference><Reference><Citation>Austin D, McCanny P, Aneman A. Post-operative renal failure management in mechanical circulatory support patients. Ann Transl Med. 2020;8(13):833. https://doi.org/10.21037/atm-20-1172.</Citation></Reference><Reference><Citation>SAS. Predictive and specialized modeling. In: JMP<sup>&#xae;</sup> 17 Documentation Library. Cary, NC: JMP Statistical Discovery LLC; 2023; 3551&#x2013;4150.</Citation></Reference><Reference><Citation>Yin EB. Anticoagulation management in temporary mechanical circulatory support devices. Tex Heart Inst J. 2023;50(4):e231835. https://doi.org/10.14503/THIJ-23-8135.</Citation></Reference><Reference><Citation>Hirsh J, O&#x2019;Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation. 2007;116(5):552&#x2013;560. https://doi.org/10.1161/CIRCULATIONAHA.106.685974.</Citation></Reference><Reference><Citation>Kaur J, Arsene C, Yadav SK, et al. Risk factors in hospitalized patients for heparin-induced thrombocytopenia by real world database: a new role for primary hypercoagulable states. J Hematol. 2021;10(4):171&#x2013;177. https://doi.org/10.14740/jh876.</Citation></Reference><Reference><Citation>Casans-Tormo I, Alcala-Lopez JE, Espinet-Coll C, Pubul-Nunez V, Martinez-Rodriguez I. (18)F-FDG PET/CT in cardiovascular infection and inflammation. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2021;40(6):397&#x2013;408. https://doi.org/10.1016/j.remnie.2021.09.008.</Citation></Reference><Reference><Citation>Kanji R, Vandenbriele C, Arachchillage DRJ, Price S, Gorog DA. Optimal tests to minimise bleeding and ischaemic complications in patients on extracorporeal membrane oxygenation. Thromb Haemost. 2022;122(4):480&#x2013;491. https://doi.org/10.1055/a-1508-8230.</Citation></Reference><Reference><Citation>Beam AL, Kohane IS. Big data and machine learning in health care. JAMA. 2018;319(13):1317&#x2013;1318. https://doi.org/10.1001/jama.2017.18391.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40053846</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1543-8392</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>Molecular pharmaceutics</Title><ISOAbbreviation>Mol Pharm</ISOAbbreviation></Journal><ArticleTitle>Multitask Deep Learning Models of Combined Industrial Absorption, Distribution, Metabolism, and Excretion Datasets to Improve Generalization.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.molpharmaceut.4c01086</ELocationID><Abstract><AbstractText>The optimization of absorption, distribution, metabolism, and excretion (ADME) profiles of compounds is critical to the drug discovery process. As such, machine learning (ML) models for ADME are widely used for prioritizing the design and synthesis of compounds. The effectiveness of ML models for ADME depends on the availability of high-quality experimental data for a diverse set of compounds that is relevant to the emerging chemical space being explored by the drug discovery teams. To that end, ADME data sets from Genentech and Roche were combined to evaluate the impact of expanding the chemical space on the performance of ML models, a first experiment of its kind for large-scale, historical ADME data sets. The combined ADME data set consisted of over 1 million individual measurements distributed across 11 assay end points. We utilized a multitask (MT) neural network architecture that enables the modeling of multiple end points simultaneously and thereby exploits information transfer between interconnected ADME end points. Both single- and cross-site MT models were trained and compared against single-site, single-task baseline models. Given the differences in assay protocols across the two sites, the data for corresponding end points across sites were modeled as separate tasks. Models were evaluated against test sets representing varying degrees of extrapolation difficulty, including cluster-based, temporal, and external test sets. We found that cross-site MT models appeared to provide a greater generalization capacity compared to single-site models. The performance improvement of the cross-site MT models was more pronounced for the relatively "distant" external and temporal test sets, suggesting an expanded applicability domain. The data exchange exercise described here demonstrates the value of expanding the learning from ADME data from multiple sources without the need to aggregate such data when the experimental methods are disparate.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Napoli</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0009-0006-5091-4355</Identifier><AffiliationInfo><Affiliation>Drug Metabolism &amp; Pharmacokinetics (DMPK), Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reutlinger</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd., Pharma Research &amp; Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandl</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd., Pharma Research &amp; Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wenyi</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Drug Metabolism &amp; Pharmacokinetics (DMPK), Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hert</LastName><ForeName>J&#xe9;r&#xf4;me</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd., Pharma Research &amp; Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Prashant</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2493-8218</Identifier><AffiliationInfo><Affiliation>Drug Metabolism &amp; Pharmacokinetics (DMPK), Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Pharm</MedlineTA><NlmUniqueID>101197791</NlmUniqueID><ISSNLinking>1543-8384</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ADME models</Keyword><Keyword MajorTopicYN="N">data sharing for machine learning</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">model generalization</Keyword><Keyword MajorTopicYN="N">multitask neural network models</Keyword><Keyword MajorTopicYN="N">temporal test sets</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>15</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40053846</ArticleId><ArticleId IdType="doi">10.1021/acs.molpharmaceut.4c01086</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40053821</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-9159</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>International journal of surgery (London, England)</Title><ISOAbbreviation>Int J Surg</ISOAbbreviation></Journal><ArticleTitle>Correlation of noninvasive imaging of tumour-infiltrating lymphocytes with survival and BCG immunotherapy response in patients with bladder cancer: a multicentre cohort study.</ArticleTitle><Pagination><StartPage>920</StartPage><EndPage>931</EndPage><MedlinePgn>920-931</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JS9.0000000000001999</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Tumour-infiltrating lymphocytes (TILs) are strongly correlated with the prognosis and immunotherapy response in bladder cancer. The TIL status is typically assessed through microscopy as part of tissue pathology. Here, the authors developed Rad-TIL model, a novel radiomics model, to predict TIL status in patients with bladder cancer.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">The authors enrolled 1089 patients with bladder cancer and developed the Rad-TIL model by using a machine-learning method based on computed tomography (CT) images. The authors applied a radiogenomics cohort to reveal the key pathways underlying the Rad-TIL model. Finally, the authors used an independent treatment cohort to evaluate the predictive efficacy of the Rad-TIL model for Bacillus Calmette-Gu&#xe9;rin (BCG) immunotherapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The authors developed the Rad-TIL model by integrating tumoral and peritumoral features on CT images and obtained areas under the receiver operating characteristic curves of 0.844 and 0.816 in the internal and external validation cohorts, respectively. Patients were stratified into two groups based on the predicted radiomics score of TILs (RSTIL). RSTIL exhibited prognostic significance for both overall and cancer-specific survival in each cohort (hazard ratios: 2.27-3.15, all P&lt;0.05). Radiogenomics analysis revealed a significant association of RSTIL with immunoregulatory pathways and immune checkpoint molecules (all P&lt;0.05). Notably, BCG immunotherapy response rates were significantly higher in high-RSTIL patients than in low-RSTIL patients (P=0.007).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The Rad-TIL model, a noninvasive method for assessing TIL status, can predict clinical outcomes and BCG immunotherapy response in patients with bladder cancer.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaoyang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Urology, The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen (Zhongshan) University, Guangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Libo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Weiming</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Urology, The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Junyu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Mingchao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xiaodong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Bohao</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Urology, The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen (Zhongshan) University, Guangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Tenghao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Urology, The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen (Zhongshan) University, Guangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Wang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Urology, The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen (Zhongshan) University, Guangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Tianxin</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Wenlong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT06381895</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Surg</MedlineTA><NlmUniqueID>101228232</NlmUniqueID><ISSNLinking>1743-9159</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001500">BCG Vaccine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001749" MajorTopicYN="Y">Urinary Bladder Neoplasms</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016246" MajorTopicYN="Y">Lymphocytes, Tumor-Infiltrating</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001500" MajorTopicYN="Y">BCG Vaccine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="Y">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>14</Hour><Minute>47</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40053821</ArticleId><ArticleId IdType="doi">10.1097/JS9.0000000000001999</ArticleId><ArticleId IdType="pii">01279778-202501000-00085</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 2017;71:96&#x2013;108.</Citation></Reference><Reference><Citation>Flaig TW, Spiess PE, Agarwal N, et al. NCCN guidelines insights: bladder cancer, Version 5.2018. J Natl Compr Canc Netw 2018;16:1041&#x2013;1053.</Citation></Reference><Reference><Citation>Shi MJ, Meng XY, Fontugne J, et al. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer. Genome Med 2020;12:85; Published 2020 Sep 28.</Citation></Reference><Reference><Citation>Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016;16:275&#x2013;287.</Citation></Reference><Reference><Citation>Lai S, Liu J, Lai CH, et al. Prognostic variations between &#x2018;primary&#x2019; and &#x2018;progressive&#x2019; muscle-invasive bladder cancer following radical cystectomy: a novel propensity score-based multicenter cohort study. Int J Surg 2024;110:270&#x2013;279.</Citation></Reference><Reference><Citation>Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline. J Urol 2016;196:1021&#x2013;1029.</Citation></Reference><Reference><Citation>Claps F, Pavan N, Ongaro L, et al. BCG-unresponsive non-muscle-invasive bladder cancer: current treatment landscape and novel emerging molecular targets. Int J Mol Sci 2023;24:12596; Published 2023 Aug 9.</Citation></Reference><Reference><Citation>Tan WS, Steinberg G, Witjes JA, et al. Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group. Eur Urol Oncol 2022;5:505&#x2013;516.</Citation></Reference><Reference><Citation>Lee H, Sha D, Foster NR, et al. Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance). Ann Oncol 2020;31:487&#x2013;494.</Citation></Reference><Reference><Citation>Price G, Bouras A, Hambardzumyan D, et al. Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma. EBioMedicine 2021;69:103453.</Citation></Reference><Reference><Citation>Lang X, Green MD, Wang W, et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov 2019;9:1673&#x2013;1685.</Citation></Reference><Reference><Citation>Kuai R, Yuan W, Son S, et al. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. Sci Adv 2018;4:eaao1736.</Citation></Reference><Reference><Citation>Hendry S, Salgado R, Gevaert T, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: TIL in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol 2017;24:311&#x2013;335.</Citation></Reference><Reference><Citation>Wang B, Xie S, Bi J, et al. Elevated pre-existing lymphocytic infiltrates in tumour stroma predict poor prognosis in resectable urothelial carcinoma of the bladder. Histopathology 2019;75:354&#x2013;364.</Citation></Reference><Reference><Citation>Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology 2016;278:563&#x2013;577.</Citation></Reference><Reference><Citation>Limkin EJ, Sun R, Dercle L, et al. Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology. Ann Oncol 2017;28:1191&#x2013;1206.</Citation></Reference><Reference><Citation>Sun R, Limkin EJ, Vakalopoulou M, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 2018;19:1180&#x2013;1191.</Citation></Reference><Reference><Citation>Mathew G, Agha R. for the STROCSS Group. STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. Int J Surg 2021;96:106165.</Citation></Reference><Reference><Citation>Cheng S, Zhong W, Xia K, et al. Prognostic role of stromal tumor-infiltrating lymphocytes in locally advanced upper tract urothelial carcinoma: a retrospective multicenter study (TSU-02 study). Oncoimmunology 2021;10:1861737.</Citation></Reference><Reference><Citation>Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TIL) in breast cancer: recommendations by an International TIL Working Group 2014. Ann Oncol 2015;26:259&#x2013;271.</Citation></Reference><Reference><Citation>Abuhadra N, Sun R, Yam C, et al. Predictive roles of baseline stromal tumor-infiltrating lymphocytes and ki-67 in pathologic complete response in an early-stage triple-negative breast cancer prospective trial. Cancers (Basel) 2023;15:3275.</Citation></Reference><Reference><Citation>Su GH, Xiao Y, Jiang L, et al. Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer. J Transl Med 2022;20:471; Published 2022 Oct 15.</Citation></Reference><Reference><Citation>Wang B, Pan W, Yang M, et al. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. Cancer Sci 2019;110:489&#x2013;498.</Citation></Reference><Reference><Citation>Wei Z, Xv Y, Liu H, et al. A CT-based deep learning model predicts overall survival in patients with muscle invasive bladder cancer after radical cystectomy: a multicenter retrospective cohort study. Int J Surg 2024;110:2922&#x2013;2932.</Citation></Reference><Reference><Citation>Zoidakis J. Simple and efficient stratification of invasive bladder cancer patients. EBioMedicine 2016;12:6&#x2013;7.</Citation></Reference><Reference><Citation>Hautmann RE, de Petriconi RC, Pfeiffer C, et al. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 2012;61:1039&#x2013;1047.</Citation></Reference><Reference><Citation>Wang Q, Xiang Q, Yu L, et al. Changes in tumor-infiltrating lymphocytes and vascular normalization in breast cancer patients after neoadjuvant chemotherapy and their correlations with DFS. Front Oncol 2020;9:1545; [Published correction appears in Front Oncol. 2021 Mar 01;11:661782]Published 2020 Jan 22.</Citation></Reference><Reference><Citation>Krpina K, Babarovi&#x107; E, Jonji&#x107; N. Correlation of tumor-infiltrating lymphocytes with bladder cancer recurrence in patients with solitary low-grade urothelial carcinoma. Virchows Arch 2015;467:443&#x2013;448.</Citation></Reference><Reference><Citation>Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 2007;104:3967&#x2013;3972.</Citation></Reference><Reference><Citation>Rouanne M, Betari R, Radulescu C, et al. Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer. Eur J Cancer 2019;108:111&#x2013;119.</Citation></Reference><Reference><Citation>Brown JR, Wimberly H, Lannin DR, et al. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2014;20:5995&#x2013;6005.</Citation></Reference><Reference><Citation>Xu H, Clemenceau JR, Park S, et al. Spatial heterogeneity and organization of tumor mutation burden with immune infiltrates within tumors based on whole slide images correlated with patient survival in bladder cancer. J Pathol Inform 2022;13:100105; Published 2022 May 21.</Citation></Reference><Reference><Citation>Kozikowski M, Suarez-Ibarrola R, Osiecki R, et al. Role of radiomics in the prediction of muscle-invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Focus 2022;8:728&#x2013;738.</Citation></Reference><Reference><Citation>Lin P, Wen DY, Chen L, et al. A radiogenomics signature for predicting the clinical outcome of bladder urothelial carcinoma. Eur Radiol 2020;30:547&#x2013;557.</Citation></Reference><Reference><Citation>Wo&#x17a;nicki P, Laqua FC, Messmer K, et al. Radiomics for the prediction of overall survival in patients with bladder cancer prior to radical cystectomy. Cancers (Basel) 2022;14:4449; Published 2022 Sep 13.</Citation></Reference><Reference><Citation>Zheng J, Kong J, Wu S, et al. Development of a noninvasive tool to preoperatively evaluate the muscular invasiveness of bladder cancer using a radiomics approach. Cancer 2019;125:4388&#x2013;4398.</Citation></Reference><Reference><Citation>Wu S, Zheng J, Li Y, et al. A radiomics nomogram for the preoperative prediction of lymph node metastasis in bladder cancer. Clin Cancer Res 2017;23:6904&#x2013;6911.</Citation></Reference><Reference><Citation>Jiang Y, Liang X, Han Z, et al. Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study. Lancet Digit Health 2021;3:e371&#x2013;e382.</Citation></Reference><Reference><Citation>Tian P, He B, Mu W, et al. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images. Theranostics 2021;11:2098&#x2013;2107.</Citation></Reference><Reference><Citation>Huang W, Jiang Y, Xiong W, et al. Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer. Nat Commun 2022;13:5095; Published 2022 Aug 30.</Citation></Reference><Reference><Citation>Jiang Y, Wang H, Wu J, et al. Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer. Ann Oncol 2020;31:760&#x2013;768; [Published correction appears in Ann Oncol. 2021 Apr;32(4):578]. doi:10.1016/j.annonc.2020.03.295</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2020.03.295</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhunaidi O, Zlotta AR. The use of intravesical BCG in urothelial carcinoma of the bladder. Ecancermedicalscience 2019;13:905; Published 2019 Feb 26.</Citation></Reference><Reference><Citation>Thalmann GN, Sermier A, Rentsch C, et al. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 2000;164:2129&#x2013;2133.</Citation></Reference><Reference><Citation>Qu K, Gu J, Ye Y, et al. High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: a long-term survival analysis. Oncoimmunology 2017;6:e1265719; Published 2017 Jan 3.</Citation></Reference><Reference><Citation>Zhong W, Wang B, Yu H, et al. Serum CCL27 predicts the response to Bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer. Oncoimmunology 2020;9:1776060; Published 2020 Jun 27.</Citation></Reference><Reference><Citation>Tang WJ, Kong QC, Cheng ZX, et al. Performance of radiomics models for tumour-infiltrating lymphocyte (TIL) prediction in breast cancer: the role of the dynamic contrast-enhanced (DCE) MRI phase. Eur Radiol 2022;32:864&#x2013;875.</Citation></Reference><Reference><Citation>Yu H, Meng X, Chen H, et al. Predicting the status of tumor-infiltrating lymphocytes in patients with breast cancer: usefulness of mammographic radiomics features. Front Oncol 2021;11:628577; Published 2021 Mar 11.</Citation></Reference><Reference><Citation>Park C, Jeong DY, Choi Y, et al. Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors. Front Immunol 2023;13:1038089; Published 2023 Jan 5.</Citation></Reference><Reference><Citation>Bian Y, Liu YF, Li J, et al. Machine learning for computed tomography radiomics: prediction of tumor-infiltrating lymphocytes in patients with pancreatic ductal adenocarcinoma. Pancreas 2022;51:549&#x2013;558.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40053805</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2291-9694</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2025</Year><Month>Mar</Month><Day>04</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>Performance Improvement of a Natural Language Processing Tool for Extracting Patient Narratives Related to Medical States From Japanese Pharmaceutical Care Records by Increasing the Amount of Training Data: Natural Language Processing Analysis and Validation Study.</ArticleTitle><Pagination><StartPage>e68863</StartPage><MedlinePgn>e68863</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2196/68863</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients' oral expressions serve as valuable sources of clinical information to improve pharmacotherapy. Natural language processing (NLP) is a useful approach for analyzing unstructured text data, such as patient narratives. However, few studies have focused on using NLP for narratives in the Japanese language.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We aimed to develop a high-performance NLP system for extracting clinical information from patient narratives by examining the performance progression with a gradual increase in the amount of training data.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used subjective texts from the pharmaceutical care records of Keio University Hospital from April 1, 2018, to March 31, 2019, comprising 12,004 records from 6559 cases. After preprocessing, we annotated diseases and symptoms within the texts. We then trained and evaluated a deep learning model (bidirectional encoder representations from transformers combined with a conditional random field [BERT-CRF]) through 10-fold cross-validation. The annotated data were divided into 10 subsets, and the amount of training data was progressively increased over 10 steps. We also analyzed the causes of errors. Finally, we applied the developed system to the analysis of case report texts to evaluate its usability for texts from other sources.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The F<sub>1</sub>-score of the system improved from 0.67 to 0.82 as the amount of training data increased from 1200 to 12,004 records. The F<sub>1</sub>-score reached 0.78 with 3600 records and was largely similar thereafter. As performance improved, errors from incorrect extractions decreased significantly, which resulted in an increase in precision. For case reports, the F<sub>1</sub>-score also increased from 0.34 to 0.41 as the training dataset expanded from 1200 to 12,004 records. Performance was lower for extracting symptoms from case report texts compared with pharmaceutical care records, suggesting that this system is more specialized for analyzing subjective data from pharmaceutical care records.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We successfully developed a high-performance system specialized in analyzing subjective data from pharmaceutical care records by training a large dataset, with near-complete saturation of system performance with about 3600 training records. This system will be useful for monitoring symptoms, offering benefits for both clinical practice and research.</AbstractText><CopyrightInformation>&#xa9;Yukiko Ohno, Tohru Aomori, Tomohiro Nishiyama, Riri Kato, Reina Fujiki, Haruki Ishikawa, Keisuke Kiyomiya, Minae Isawa, Mayumi Mochizuki, Eiji Aramaki, Hisakazu Ohtani. Originally published in JMIR Medical Informatics (https://medinform.jmir.org), 04.03.2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ohno</LastName><ForeName>Yukiko</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0001-2378-2629</Identifier><AffiliationInfo><Affiliation>Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aomori</LastName><ForeName>Tohru</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7697-6446</Identifier><AffiliationInfo><Affiliation>Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishiyama</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1538-8266</Identifier><AffiliationInfo><Affiliation>Nara Institute of Science and Technology, Ikoma, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Riri</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0007-0029-743X</Identifier><AffiliationInfo><Affiliation>Faculty of Pharmacy, Keio University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujiki</LastName><ForeName>Reina</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0005-8682-9294</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Keio University Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishikawa</LastName><ForeName>Haruki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0004-0633-5482</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Keio University Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiyomiya</LastName><ForeName>Keisuke</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0004-1586-6357</Identifier><AffiliationInfo><Affiliation>Faculty of Pharmacy, Keio University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isawa</LastName><ForeName>Minae</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0007-3068-0800</Identifier><AffiliationInfo><Affiliation>Faculty of Pharmacy, Keio University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mochizuki</LastName><ForeName>Mayumi</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6772-4327</Identifier><AffiliationInfo><Affiliation>Faculty of Pharmacy, Keio University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aramaki</LastName><ForeName>Eiji</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-0201-3609</Identifier><AffiliationInfo><Affiliation>Nara Institute of Science and Technology, Ikoma, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohtani</LastName><ForeName>Hisakazu</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4089-9407</Identifier><AffiliationInfo><Affiliation>Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Keio University Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Keio University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID><ISSNLinking>2291-9694</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D009323" MajorTopicYN="Y">Natural Language Processing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033262" MajorTopicYN="Y">Narration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077321" MajorTopicYN="N">Deep Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010593" MajorTopicYN="N">Pharmaceutical Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000095225" MajorTopicYN="N">East Asian People</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EMR</Keyword><Keyword MajorTopicYN="N">Japanese</Keyword><Keyword MajorTopicYN="N">NER</Keyword><Keyword MajorTopicYN="N">NLP</Keyword><Keyword MajorTopicYN="N">deep learning</Keyword><Keyword MajorTopicYN="N">electronic medical record</Keyword><Keyword MajorTopicYN="N">named entity recognition</Keyword><Keyword MajorTopicYN="N">natural language processing</Keyword><Keyword MajorTopicYN="N">pharmaceutical care record</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>14</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40053805</ArticleId><ArticleId IdType="doi">10.2196/68863</ArticleId><ArticleId IdType="pii">v13i1e68863</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40053794</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1438-8871</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><PubDate><Year>2025</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>Journal of medical Internet research</Title><ISOAbbreviation>J Med Internet Res</ISOAbbreviation></Journal><ArticleTitle>Machine Learning-Based Prediction of Early Complications Following Surgery for Intestinal Obstruction: Multicenter Retrospective Study.</ArticleTitle><Pagination><StartPage>e68354</StartPage><MedlinePgn>e68354</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2196/68354</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Early complications increase in-hospital stay and mortality after intestinal obstruction surgery. It is important to identify the risk of postoperative early complications for patients with intestinal obstruction at a sufficiently early stage, which would allow preemptive individualized enhanced therapy to be conducted to improve the prognosis of patients with intestinal obstruction. A risk predictive model based on machine learning is helpful for early diagnosis and timely intervention.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to construct an online risk calculator for early postoperative complications in patients after intestinal obstruction surgery based on machine learning algorithms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 396 patients undergoing intestinal obstruction surgery from April 2013 to April 2021 at an independent medical center were enrolled as the training cohort. Overall, 7 machine learning methods were used to establish prediction models, with their performance appraised via the area under the receiver operating characteristic curve (AUROC), accuracy, sensitivity, specificity, and F<sub>1</sub>-score. The best model was validated through 2 independent medical centers, a publicly available perioperative dataset the Informative Surgical Patient dataset for Innovative Research Environment (INSPIRE), and a mixed cohort consisting of the above 3 datasets, involving 50, 66, 48, and 164 cases, respectively. Shapley Additive Explanations were measured to identify risk factors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The incidence of postoperative complications in the training cohort was 47.44% (176/371), while the incidences in 4 external validation cohorts were 34% (17/50), 56.06% (37/66), 52.08% (25/48), and 48.17% (79/164), respectively. Postoperative complications were associated with 8-item features: Physiological Severity Score for the Enumeration of Mortality and Morbidity (POSSUM physiological score), the amount of colloid infusion, shock index before anesthesia induction, ASA (American Society of Anesthesiologists) classification, the percentage of neutrophils, shock index at the end of surgery, age, and total protein. The random forest model showed the best overall performance, with an AUROC of 0.788 (95% CI 0.709-0.869), accuracy of 0.756, sensitivity of 0.695, specificity of 0.810, and F<sub>1</sub>-score of 0.727 in the training cohort. The random forest model also achieved a comparable AUROC of 0.755 (95% CI 0.652-0.839) in validation cohort 1, a greater AUROC of 0.817 (95% CI 0.695-0.913) in validation cohort 2, a similar AUROC of 0.786 (95% CI 0.628-0.902) in validation cohort 3, and the comparable AUROC of 0.720 (95% CI 0.671-0.768) in validation cohort 4. We visualized the random forest model and created a web-based online risk calculator.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We have developed and validated a generalizable random forest model to predict postoperative early complications in patients undergoing intestinal obstruction surgery, enabling clinicians to screen high-risk patients and implement early individualized interventions. An online risk calculator for early postoperative complications was developed to make the random forest model accessible to clinicians around the world.</AbstractText><CopyrightInformation>&#xa9;Pinjie Huang, Jirong Yang, Dizhou Zhao, Taojia Ran, Yuheng Luo, Dong Yang, Xueqin Zheng, Shaoli Zhou, Chaojin Chen. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 03.03.2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Huang</LastName><ForeName>Pinjie</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7909-9901</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Jirong</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0004-2775-2760</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhao</LastName><ForeName>Dizhou</ForeName><Initials>D</Initials><Identifier Source="ORCID">0009-0002-1305-3964</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, ShenZhen People's Hospital, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ran</LastName><ForeName>Taojia</ForeName><Initials>T</Initials><Identifier Source="ORCID">0009-0000-7509-3633</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Yuheng</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-8920-8390</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Dong</ForeName><Initials>D</Initials><Identifier Source="ORCID">0009-0007-9471-9292</Identifier><AffiliationInfo><Affiliation>Guangzhou AI &amp; Data Cloud Technology Co., Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Xueqin</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-6254-1051</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, First People's Hospital of Foshan, Foshan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Shaoli</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6604-0166</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chaojin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5101-4101</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Med Internet Res</MedlineTA><NlmUniqueID>100959882</NlmUniqueID><ISSNLinking>1438-8871</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007415" MajorTopicYN="Y">Intestinal Obstruction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Shapley additive explanations</Keyword><Keyword MajorTopicYN="N">early intervention</Keyword><Keyword MajorTopicYN="N">intestinal obstruction</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">postoperative complications</Keyword><Keyword MajorTopicYN="N">prediction model</Keyword><Keyword MajorTopicYN="N">risk calculator</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>14</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40053794</ArticleId><ArticleId IdType="doi">10.2196/68354</ArticleId><ArticleId IdType="pii">v27i1e68354</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40053791</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1438-8871</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><PubDate><Year>2025</Year><Month>Mar</Month><Day>06</Day></PubDate></JournalIssue><Title>Journal of medical Internet research</Title><ISOAbbreviation>J Med Internet Res</ISOAbbreviation></Journal><ArticleTitle>Machine Learning Models With Prognostic Implications for Predicting Gastrointestinal Bleeding After Coronary Artery Bypass Grafting and Guiding Personalized Medicine: Multicenter Cohort Study.</ArticleTitle><Pagination><StartPage>e68509</StartPage><MedlinePgn>e68509</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2196/68509</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Gastrointestinal bleeding is a serious adverse event of coronary artery bypass grafting and lacks tailored risk assessment tools for personalized prevention.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aims to develop and validate predictive models to assess the risk of gastrointestinal bleeding after coronary artery bypass grafting (GIBCG) and to guide personalized prevention.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants were recruited from 4 medical centers, including a prospective cohort and the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. From an initial cohort of 18,938 patients, 16,440 were included in the final analysis after applying the exclusion criteria. Thirty combinations of machine learning algorithms were compared, and the optimal model was selected based on integrated performance metrics, including the area under the receiver operating characteristic curve (AUROC) and the Brier score. This model was then developed into a web-based risk prediction calculator. The Shapley Additive Explanations method was used to provide both global and local explanations for the predictions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The model was developed using data from 3 centers and a prospective cohort (n=13,399) and validated on the Drum Tower cohort (n=2745) and the MIMIC cohort (n=296). The optimal model, based on 15 easily accessible admission features, demonstrated an AUROC of 0.8482 (95% CI 0.8328-0.8618) in the derivation cohort. In external validation, the AUROC was 0.8513 (95% CI 0.8221-0.8782) for the Drum Tower cohort and 0.7811 (95% CI 0.7275-0.8343) for the MIMIC cohort. The analysis indicated that high-risk patients identified by the model had a significantly increased mortality risk (odds ratio 2.98, 95% CI 1.784-4.978; P&lt;.001). For these high-risk populations, preoperative use of proton pump inhibitors was an independent protective factor against the occurrence of GIBCG. By contrast, dual antiplatelet therapy and oral anticoagulants were identified as independent risk factors. However, in low-risk populations, the use of proton pump inhibitors (&#x3c7;<sup>2</sup><sub>1</sub>=0.13, P=.72), dual antiplatelet therapy (&#x3c7;<sup>2</sup><sub>1</sub>=0.38, P=.54), and oral anticoagulants (&#x3c7;<sup>2</sup><sub>1</sub>=0.15, P=.69) were not significantly associated with the occurrence of GIBCG.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our machine learning model accurately identified patients at high risk of GIBCG, who had a poor prognosis. This approach can aid in early risk stratification and personalized prevention.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Chinese Clinical Registry Center ChiCTR2400086050; http://www.chictr.org.cn/showproj.html?proj=226129.</AbstractText><CopyrightInformation>&#xa9;Jiale Dong, Zhechuan Jin, Chengxiang Li, Jian Yang, Yi Jiang, Zeqian Li, Cheng Chen, Bo Zhang, Zhaofei Ye, Yang Hu, Jianguo Ma, Ping Li, Yulin Li, Dongjin Wang, Zhili Ji. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 06.03.2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Dong</LastName><ForeName>Jiale</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0008-3275-3791</Identifier><AffiliationInfo><Affiliation>Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Acute Abdomen Surgery, Beijing ChaoYang Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Jin</LastName><ForeName>Zhechuan</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0009-0000-3804-1172</Identifier><AffiliationInfo><Affiliation>Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chengxiang</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0007-5096-9513</Identifier><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0005-1860-793X</Identifier><AffiliationInfo><Affiliation>Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0622-0699</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Nanjing Drum Tower Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zeqian</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0009-0008-9840-595X</Identifier><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3619-871X</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><Identifier Source="ORCID">0009-0003-2474-6237</Identifier><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Surgery, Beijing Luhe Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Zhaofei</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0009-0009-3138-8160</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0393-7814</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jianguo</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7522-1014</Identifier><AffiliationInfo><Affiliation>School of Instrumentation and Optoelectronic Engineering, Beihang University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ping</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6121-8367</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Yulin</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-7909-0763</Identifier><AffiliationInfo><Affiliation>Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Dongjin</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4130-5391</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ji</LastName><ForeName>Zhili</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0009-0007-6642-6652</Identifier><AffiliationInfo><Affiliation>Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Acute Abdomen Surgery, Beijing ChaoYang Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Med Internet Res</MedlineTA><NlmUniqueID>100959882</NlmUniqueID><ISSNLinking>1438-8871</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006471" MajorTopicYN="Y">Gastrointestinal Hemorrhage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="Y">Precision Medicine</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001026" MajorTopicYN="Y">Coronary Artery Bypass</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adverse outcome</Keyword><Keyword MajorTopicYN="N">coronary artery bypass grafting</Keyword><Keyword MajorTopicYN="N">gastrointestinal bleeding</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">personalized medicine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>14</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40053791</ArticleId><ArticleId IdType="doi">10.2196/68509</ArticleId><ArticleId IdType="pii">v27i1e68509</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>